2:45 p.m. – SARS-CoV-2: a seroprevalence point in France
Public Health France (SPF) publishes the first results of a seroprevalence survey that it is conducting with the Institut Pasteur in Paris and the ANSES (National Health Security Agency).
SPF writes that the “proportion of people carrying anti-SARS-CoV-2 antibodies acquired after infection or vaccination, increased very sharply in week 23-2021 (June 07-13), reaching 52.4% against 13.7% during the week 06-2021 (08-14 February)“. And to continue:”The increase in seroprevalence observed for all age groups was greater in adults and markedly more marked in those aged 60 and over. “. The agency concludes “these results will soon be refined by new analyzes but already suggest a significant gain in immunity in the French population, in connection with vaccination, with seroprevalences much higher than those observed during previous epidemic waves. Seroprevalence is in fact highest in the age groups initially targeted by vaccination campaigns, and lower in young people to whom vaccination was offered later, at the end of May (from 18 years old) and mid-June ( from 12 years old)“.
Prevalence of anti-SARS-CoV-2 antibodies by age group, France *
* excluding Mayotte for insufficient number of samples ** provisional estimates adjusted for a single measurement point
2 p.m. – Third dose: very reserved experts
In The Lancet, experts from different countries, including some members of the WHO (World Health Organization) and the FDA (Food and drug administration) write: “While the idea of further reducing the number of COVID-19 cases by boosting the immunity of those vaccinated is appealing, any such decision must be evidence-based and consider the benefits and risks to individuals and the society. “. They continue”Careful and public scrutiny of evolving data will be needed to ensure decisions about boosting are based on sound science rather than political considerations. Even if the booster turns out to decrease the risk of severe illness in the medium term, current vaccine stocks could save more lives if used in previously unvaccinated populations than if used as a booster in the past. of vaccinated populations“.
Considerations in boosting COVID-19 vaccine immune
1 p.m. – A genetically modified DNA vaccine in India
India has authorized the world’s first genetically modified DNA vaccine: ZyCoV-D. It is 66% effective in protecting against severe forms of Covid-19.
12 p.m. – Canberra lockdown extended by one month
The sanction fell for the inhabitants of Canberra. The inhabitants of the Australian megalopolis will have to remain confined until mid-October. They have already been confined for a month, in a context of limited dissemination of the Delta variant.
11 a.m. – IMF grants $ 567 million to Tanzania
The International Monetary Fund grants Tanzania a loan of 567 million dollars (478 million euros) to finance the “urgent” needs of its economy hard hit by the effects of the coronavirus pandemic.
10 a.m. – Less than 10,000 people hospitalized for Covid in France
– 6,907,133 SARS-CoV-2 infections have been identified since March 1, 2020 (67,639 in one week, 2,062 in the last 24 hours),
– 115,603 deaths (596 in one week, 86 yesterday),
– 9,986 people hospitalized for Covid (+ 773 in one week)
– 2,103 people hospitalized in intensive care for Covid (+ 146 in one week).
9 a.m. – Update on the world
According to the latest available data, 225,359,152 infections (17,319,973 in the last four weeks) by SARS-CoV-2 have been identified worldwide and 4,641,746 deaths (267,809 in the last four weeks) associated with Covid have been reported since the start of the pandemic. In the past four weeks, the three countries that have identified the most cases are the United States (4,317,653 cases), India (1,038,900 cases) and the United Kingdom (964,653 cases). The three countries that have had the highest number of deaths from Covid in absolute terms in the past four weeks are the United States (39,380 deaths), Russia (21,647 deaths), Indonesia (20,332 deaths).